Sign In

Jeroen Verheyen

Co-Founder & CEO at Semarion

Jeroen Verheyen is the Co-Founder and CEO of Semarion, a company operating at the intersection of emerging technologies and life sciences.1 He is actively involved in the development and promotion of Semarion's innovative technologies, particularly their SemaCyte® platform.2

Professional Background

Verheyen has a strong educational foundation, having studied at the University of Cambridge.1 His expertise lies in bridging the gap between cutting-edge technologies and their applications in the life sciences sector.

Achievements and Recognition

Industry Awards:: In 2024, Semarion, under Verheyen's leadership, won the SLAS Europe Ignite Award.2 This recognition highlights the company's innovative contributions to the field.

Personal Accolades:: In 2022, Verheyen was named in cofinitive's #21toWatch final Top21.2022, acknowledging his potential as a rising innovator in the industry.3

Professional Activities

Verheyen is actively engaged in promoting Semarion's technologies and participating in industry events:

  • He has given interviews discussing the transformative potential of Semarion's SemaCyte® technology.2
  • Semarion participates in events like ELRIG UK's Research & Innovation conference, showcasing their novel technologies to the drug discovery community.4
  • Verheyen advocates for the adoption of new innovations in drug discovery, particularly in the TechBio sector.5

Through his role at Semarion, Jeroen Verheyen is working to advance technologies that have the potential to significantly impact drug discovery and life sciences research.

Highlights

Jul 1 · linkedin

Excited to share insights from my recent interview with the Technology Networks on the transformative potential of Semarion's SemaCyte® platform and our journey to winning the SLAS (Society for Laboratory Automation and Screening) Ignite Award.

The rapid advancements in cell-based assays and screening are revolutionizing drug discovery by enhancing speed, accuracy, and efficiency. There is a drive to investigate complexity at scale and produce more physiologically relevant data faster and earlier in the drug discovery process.

At Semarion, we’re at the forefront of this transformation with our innovative SemaCyte® technology, which turns adherent cells into liquid reagents. This breakthrough drastically improves the scalability, reliability, and throughput of cell assays, accelerating data generation and reducing costs.

Key highlights from the interview: 🔬 SemaCyte® Platform: Our microcarrier technology barcodes and mobalises adherent cells, enabling next gen automation and miniaturization. This streamlines workflows and supercharges high-content, high-throughput data generation. ❄️ Cryopreservation: By cryopreserving assay-ready cells, we eliminate lengthy preparation times and batch variability, making the process more efficient and reliable. 🔍 Multiplexing & Miniaturization: The platform supports multiplexing different cell types in a single well and reduces the number of cells needed, enhancing the efficiency and cost-effectiveness of drug discovery.

We envision a future where advanced materials science, automation, and data analytics converge to further accelerate and refine the drug discovery process. Platforms like SemaCyte® will be pivotal in driving these changes, facilitating faster, more precise, and scalable research.

A big thank you to SLAS for recognizing our efforts with the Ignite Award and to Technology Networks for the opportunity to discuss our work.

Read the full interview here: https://lnkd.in/euHMBPGy

To learn more about what Semarion does, visit www.semarion.com. Feel free to reach out for more information and access to our technology.

#drugdiscovery #biotechnology #innovation #SLAS2024 #SemaCyte #Semarion #cellassays #biopharma #automation #datageneration

Mar 22 · linkedin

We had a great time at ELRIG UK's Research & Innovation conference in Manchester.

The Breakthrough Zone, which Semarion was part of, was buzzing with cutting edge life science innovation, attracting lots of interest from the delegates. Keep your eyes out for the next opportunity to showcase your novel tech to the ELRIG's vast drug discovery community. It is certainly worth it.

My favorite talk: CAR-T cell therapy development from concept to cure (by Sabrina de Munnik at Charles River Laboratories).

My favorite poster: Mechanistic prediction of genotoxicity using cell painting (by Elizabeth Mouchet at AstraZeneca).

Thanks to Zyme Communications Ltd, Molly Rose Campbell, and Kath Darlington for featuring us. It was great to talk about how Semarion is transforming cell assay workflows to drive 10x gains in throughput.

Related Questions

What is Semarion's SemaCyte® technology?
How did Jeroen Verheyen start his career in life sciences?
What are some notable achievements of Semarion under Jeroen Verheyen's leadership?
What other companies has Jeroen Verheyen worked for?
How did Jeroen Verheyen's education at the University of Cambridge influence his career?
Jeroen Verheyen
Jeroen Verheyen, photo 1
Jeroen Verheyen, photo 2
Add to my network

Location

Greater Cambridge Area